ID: ALA151393

Max Phase: Preclinical

Molecular Formula: C17H27N3O9

Molecular Weight: 417.42

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)NC[C@H]1O[C@@H](OC[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C17H27N3O9/c1-7(2)18-5-8-11(22)14(25)16(29-8)27-6-9-12(23)13(24)15(28-9)20-4-3-10(21)19-17(20)26/h3-4,7-9,11-16,18,22-25H,5-6H2,1-2H3,(H,19,21,26)/t8-,9-,11-,12-,13-,14-,15-,16-/m1/s1

Standard InChI Key:  HUBZSIXTMNNPKC-YDBCPLSKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 417.42

Molecular Weight (Monoisotopic): 417.1747

AlogP: -3.38

#Rotatable Bonds: 7

Polar Surface Area: 175.50

Molecular Species: BASE

HBA: 11

HBD: 6

#RO5 Violations: 2

HBA (Lipinski): 12

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 9.70

CX Basic pKa: 9.08

CX LogP: -2.94

CX LogD: -4.25

Aromatic Rings: 1

Heavy Atoms: 29

QED Weighted: 0.26

Np Likeness Score: 1.20

References

1. Dini C, Drochon N, Feteanu S, Guillot JC, Peixoto C, Aszodi J..  (2001)  Synthesis of analogues of the O-beta-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 1: contribution of the amino group and the uracil moiety upon the inhibition of MraY.,  11  (4): [PMID:11229763] [10.1016/s0960-894x(00)00715-0]

2. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G..  (2019)  Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.,  171  [PMID:30933853] [10.1016/j.ejmech.2019.01.071]

Source

Source(1):

• Scientific Literature